Back to Search Start Over

Variants at the Interleukin 1 Gene Locus and Pericarditis.

Authors :
Thorolfsdottir RB
Jonsdottir AB
Sveinbjornsson G
Aegisdottir HM
Oddsson A
Stefansson OA
Halldorsson GH
Saevarsdottir S
Thorleifsson G
Stefansdottir L
Pedersen OB
Sørensen E
Ghouse J
Raja AA
Zheng C
Silajdzija E
Rand SA
Erikstrup C
Ullum H
Mikkelsen C
Banasik K
Brunak S
Ivarsdottir EV
Sigurdsson A
Beyter D
Sturluson A
Einarsson H
Tragante V
Helgason H
Lund SH
Halldorsson BV
Sigurpalsdottir BD
Olafsson I
Arnar DO
Thorgeirsson G
Knowlton KU
Nadauld LD
Gretarsdottir S
Helgadottir A
Ostrowski SR
Gudbjartssson DF
Jonsdottir I
Bundgaard H
Holm H
Sulem P
Stefansson K
Source :
JAMA cardiology [JAMA Cardiol] 2024 Feb 01; Vol. 9 (2), pp. 165-172.
Publication Year :
2024

Abstract

Importance: Recurrent pericarditis is a treatment challenge and often a debilitating condition. Drugs inhibiting interleukin 1 cytokines are a promising new treatment option, but their use is based on scarce biological evidence and clinical trials of modest sizes, and the contributions of innate and adaptive immune processes to the pathophysiology are incompletely understood.<br />Objective: To use human genomics, transcriptomics, and proteomics to shed light on the pathogenesis of pericarditis.<br />Design, Setting, and Participants: This was a meta-analysis of genome-wide association studies of pericarditis from 5 countries. Associations were examined between the pericarditis-associated variants and pericarditis subtypes (including recurrent pericarditis) and secondary phenotypes. To explore mechanisms, associations with messenger RNA expression (cis-eQTL), plasma protein levels (pQTL), and CpG methylation of DNA (ASM-QTL) were assessed. Data from Iceland (deCODE genetics, 1983-2020), Denmark (Copenhagen Hospital Biobank/Danish Blood Donor Study, 1977-2022), the UK (UK Biobank, 1953-2021), the US (Intermountain, 1996-2022), and Finland (FinnGen, 1970-2022) were included. Data were analyzed from September 2022 to August 2023.<br />Exposure: Genotype.<br />Main Outcomes and Measures: Pericarditis.<br />Results: In this genome-wide association study of 4894 individuals with pericarditis (mean [SD] age at diagnosis, 51.4 [17.9] years, 2734 [67.6%] male, excluding the FinnGen cohort), associations were identified with 2 independent common intergenic variants at the interleukin 1 locus on chromosome 2q14. The lead variant was rs12992780 (T) (effect allele frequency [EAF], 31%-40%; odds ratio [OR], 0.83; 95% CI, 0.79-0.87; P = 6.67 × 10-16), downstream of IL1B and the secondary variant rs7575402 (A or T) (EAF, 45%-55%; adjusted OR, 0.89; 95% CI, 0.85-0.93; adjusted P = 9.6 × 10-8). The lead variant rs12992780 had a smaller odds ratio for recurrent pericarditis (0.76) than the acute form (0.86) (P for heterogeneity = .03) and rs7575402 was associated with CpG methylation overlapping binding sites of 4 transcription factors known to regulate interleukin 1 production: PU.1 (encoded by SPI1), STAT1, STAT3, and CCAAT/enhancer-binding protein β (encoded by CEBPB).<br />Conclusions and Relevance: This study found an association between pericarditis and 2 independent sequence variants at the interleukin 1 gene locus. This finding has the potential to contribute to development of more targeted and personalized therapy of pericarditis with interleukin 1-blocking drugs.

Details

Language :
English
ISSN :
2380-6591
Volume :
9
Issue :
2
Database :
MEDLINE
Journal :
JAMA cardiology
Publication Type :
Academic Journal
Accession number :
38150231
Full Text :
https://doi.org/10.1001/jamacardio.2023.4820